Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.9 million.

  • Rhythm Pharmaceuticals' Income from Continuing Operations fell 21.23% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 25.72%. This contributed to the annual value of -$260.6 million for FY2024, which is 41.11% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Income from Continuing Operations is -$52.9 million, which was down 13.45% from -$46.6 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Income from Continuing Operations peaked at $43.8 million during Q1 2021, and registered a low of -$141.4 million during Q1 2024.
  • In the last 3 years, Rhythm Pharmaceuticals' Income from Continuing Operations had a median value of -$46.6 million in 2025 and averaged -$54.0 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 228.06% in 2021, then plummeted by 220.07% in 2022.
  • Rhythm Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$50.9 million in 2021, then increased by 16.44% to -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then declined by 3.98% to -$43.3 million in 2024, then declined by 21.23% to -$52.9 million in 2025.
  • Its Income from Continuing Operations was -$52.9 million in Q3 2025, compared to -$46.6 million in Q2 2025 and -$49.5 million in Q1 2025.